

# Dual Kidney Allocation Score: A Novel Algorithm Utilizing Expanded Donor Criteria for the Allocation of Dual Kidneys in Adults **Contact Information:** Adam P Johnson MD, MPH<sup>1</sup>; Thea P Price MD<sup>1</sup>; Benjamin Lieby PhD<sup>2</sup>; and Cataldo Doria, MD, PhD, FACS<sup>1</sup> C: 913-980-3247 Thomas Jefferson University Department of Transplant Surgery<sup>1</sup> and Department of Biostatistics<sup>2</sup>

### Background

Dual kidney transplantation (DKT) of expanded criteria donors is a cost intensive procedure to help increase the pool of available deceased organ donors. In studies to day, expanded criteria single kidney (eSKT) or dual kidney transplantation (DKT) have demonstrated equivalence, but a more rigorous allocation system is needed to optimize limited resources for improved operative outcomes.



### Materials and Methods

We analyzed United Network for Organ Sharing (UNOS) data for 1,547 DKT and 26,381 eSKT performed between January 1994 and September 2013. Of thirty-six donor variables known at the time of listing, thirteen were significantly associated with graft survival by multivariable cox regression modeling. From these variables, we derived a weighted multivariable product score from calculated hazard ratios to model the benefit 1547 Dual kidney transplant of transplantation as dual kidneys.

$$HR_{Rel} = HR_{eSKT} \div HR_{DKT}$$

737,798 patients in UNOS database from January 1994 to September 2013 → 177,129 Non-ECD Donors → 532,617 Missing 28,052 Expanded Criteria Donors 87 Other transplant (i.e. multivisceral) → 37 Missing 26,381 Single kidney transplant (129 en bloc, 1418 sequential)

Figure 1: Exclusion criteria for analysis. UNOS: United Network for Organ Sharing; ECD: Expanded Criteria Donors

 $DKAS = (HR_{Rel-Var1})^{Var1} \times (HR_{Rel-Var2})^{Var2} \times \dots \times (HR_{Rel-Var})^{Var}$ 

### Results

Differences in graft survival between dual and single transplantation were strongly correlated with our allocation score. Donors with scores less than 2.1 transplanted as dual kidneys had a worsened median survival of 594 days (24%, p-value 0.031) and donors with scores greater than 3.9 had improved median survival of 1,107 days (71%, p-value 0.002). There were 17,733 eSKT (67%) and 1,051 DKT (67%) with scores in between these values and no differences in survival (p-value 0.676 and 0.185).



Figure 3: Box Plot Distribution of DKAS between eSKT and DKT. eSKT: expanded criteria single kidney transplant; DKT: Dual kidney transplant

| Table 1: Factors associated with 5-year graft survival by multivariable cox proportional hazard model. |                  |                |                  |       |       |         |         | Table 2: Hazard ratio for full follow up and subgroup analysis for eSKT and DKT. |                                |                             |                     |                            |         |                   |
|--|------------------|----------------|------------------|-------|-------|---------|---------|--|--------------------------------|-----------------------------|---------------------|----------------------------|---------|-------------------|
| Donor Factor   | Variable<br>type | Missing<br>(%) | ECD<br>(±IQR, %) | В     | SE    | Wald    | Exp (B) | <i>p</i> -value  |                                | eSKT (n=26                  | 381)                | DKT (n=1547                | 7)      | HR <sub>Rel</sub> |
| Demographics   | "                |                |                  |       |       |         |         |  | Donor Factor                   | HR <sub>eSKT</sub> (95% CI) | p-value             | HR <sub>DKT</sub> (95% CI) | p-value |                   |
| Age (years)  | Continuous       | 0 (0)          | 60 ± 9           | 0.024 | 0.002 | 195.576 | 1.024   | <0.001   | Demographics                   |                             |                     |                            |         |                   |
| Gender—Male  | Categorical      | 0 (0)          | 13629 (48.8)     | 0.06  | 0.021 | 7.864   | 1.062   | 0.005  | Age (years)                    | 1.027 (1.024-1.031)         | <0.001              | 1.014 (1.001-1.027)        | 0.037   | 1.013             |
| Ethnicity—Black  | Categorical      | 24 (0.1)       | 3260 (11.7)      | 0.148 | 0.032 | 21.553  | 1.160   | < 0.001  | Gender—Male                    | 1.070 (1.025-1.117)         | 0.002               | 1.010 (0.842-1.211)        | 0.915   | 1.059             |
| BMI (<18.5 kg/m <sup>2</sup> )   | Categorical      | 368 (1.3)      | 588 (2.1)        | 0.191 | 0.066 | 8.231   | 1.210   | 0.004  | Ethnicity—Black                | 1.172 (1.099-1.250)         | <0.001              | 1.078 (0.839-1.383)        | 0.558   | 1.087             |
| Mechanism of Death—ICH   | Categorical      | 17 (0.1)       | 22912 (82)       | 0.113 | 0.029 | 15.366  | 1.119   | < 0.001  | BMI (<18.5 kg/m <sup>2</sup> ) | 1.200 (1.047-1.375)         | 0.011               | 1.501 (0.973-2.315)        | 0.066   | 0.799             |
| Past Medical History   |                  |                |                  |       |       |         |         | Mechanism of Death—ICH   | 1.122 (1.059-1.190)            | <0.001                      | 1.175 (0.933-1.479) | 0.171                      | 0.956   |                   |
| Diabetes (0-5 years or unknown)  | Categorical      | 234 (0.8)      | 2191 (7.8)       | 0.104 | 0.038 | 7.399   | 1.109   | 0.007  | Past Medical History           |                             |                     |                            |         |                   |
| Diabetes (5-10 years)  | Categorical      | 234 (0.8)      | 663 (2.4)        | 0.198 | 0.065 | 9.321   | 1.219   | 0.002  | Diabetes (0-5 years or unk)    | 1.136 (1.052-1.227)         | 0.001               | 0.822 (0.594-1.138)        | 0.237   | 1.382             |
| Diabetes (>10 years)   | Categorical      | 234 (0.8)      | 643 (2.3)        | 0.18  | 0.066 | 7.463   | 1,197   | 0.006  | Diabetes (5-10 years)          | 1.212 (1.061-1.384)         | 0.005               | 1.333 (0.854-2.082)        | 0.206   | 0.909             |
| Urmartancian   | Catagorical      | 208 (0.7)      | 10422 (60.5)     | 0.100 | 0.024 | 10.641  | 1.115   | -0.001   | Diabetes (>10 years)           | 1.169 (1.019-1.341)         | 0.027               | 1.516 (1.036-2.219)        | 0.032   | 0.771             |
| rypertension   | Categorical      | 208 (0.7)      | 19423 (09.3)     | 0.109 | 0.024 | 19.041  | 1.115   | <0.001   | Hypertension                   | 1.114 (1.060-1.170)         | <0.001              | 1.238 (1.014-1.513)        | 0.036   | 0.900             |
| Cigarette use (>20 pack years)   | Categorical      | 517 (1.9)      | 11743 (42)       | 0.078 | 0.021 | 13.893  | 1.081   | <0.001   | Cigarette use (>20 pack years) | 1.098 (1.053-1.145)         | <0.001              | 0.838 (0.698-1.007)        | 0.059   | 1.310             |
| Laboratory Tests   |                  |                |                  |       |       |         |         | Laboratory Tests   |                                |                             |                     |                            |         |                   |
| Terminal Creatinine (mg/dL)  | Continuous       | 67 (0.24)      | $1.0\pm0.5$      | 0.02  | 0.007 | 8.070   | 1.020   | 0.005  | Terminal Creatinine (mg/dL)    | 1.018 (1.004-1.033)         | 0.014               | 1.055 (1.007-1.104)        | 0.023   | 0.965             |
| BUN (mg/dL)  | Continuous       | 67 (0.24)      | $15\pm11$        | 0.007 | 0.001 | 52.079  | 1.007   | <0.001   | BUN (mg/dL)                    | 1.008 (1.006-1.010)         | <0.001              | 1.000 (0.992-1.008)        | 0.959   | 1.008             |
| Positive Hepatitis C Antibody Serology   | Categorical      | 86 (0.3)       | 346 (1.2)        | 0.473 | 0.082 | 33.442  | 1.606   | <0.001   | Positive Hep C Ant Serology    | 1.634 (1.387-1.925)         | <0.001              | 1.588 (0.747-3.373)        | 0.229   | 1.029             |

BMI: Body Mass Index; ICH: Intracranial hemorrhage; BUN: Blood Urea Nitrogen

| DKAS = | 1.013 <sup>Age</sup>   | X | 1.059 <sup>Male</sup>   | X | 1.087 <sup>Eth-Back</sup>      | Х |
|--------|------------------------|---|-------------------------|---|--------------------------------|---|
|        | 1.382 <sup>DM0-5</sup> | Χ | 0.909 <sup>DM5-10</sup> | Χ | 0.771 <sup>DM&gt;10</sup>      | X |
|        | 0.965 <sup>Creat</sup> | Χ | 1.008 <sup>BUN</sup>    | Х | <b>1.029</b> <sup>HepCAb</sup> |   |



Figure 2: Kaplan-Meier comparison of eSKT vs. DKT graft survival for 5 year (right) and full follow up (left). p-value determined by log rank analysis. eSKT: expanded criteria single kidney transplant; DKT: dual kidney transplant

Years DKT Events DKT At Risk eSKT Events eSKT At Risk

Figure 5: Kaplan-Meier comparison of eSKT vs. DKT graft survival for 5 year (right) and full follow up (left) for DKAS values >3.9. p-value determined by log rank analysis. eSKT: expanded criteria single kidney transplant; DKT: dual kidney transplant

## Conclusions

Our analysis shows that current allocation does not optimize the benefit of dual transplantation and we provide a new outcomes-based risk score to standardize organ allocation for dual kidney transplantation.

| Table 3: Median survival for donors stratified by DKAS.   |            |          |                  |                  |         |                     |  |  |  |
|---|------------|----------|------------------|------------------|---------|---------------------|--|--|--|
| DKAS  | N (        | %)       | Median Surviva   | l Days (95% CI)  |         | DKT Median Survival |  |  |  |
|   | eSKT       | DKT      | eSKT             | DKT              | p-value | Difference (95% CI) |  |  |  |
| < 2.1   | 5200 (20)  | 153 (10) | 2446 (2342-2549) | 1852 (1234-2469) | 0.031   | -24% (-50 – 1.2)    |  |  |  |
| 2.1-2.7   | 11620 (44) | 595 (38) | 2296 (2231-2360) | 2396 (2102-2690) | 0.676   |                     |  |  |  |
| 2.7-3.3   | 6153 (23)  | 456 (29) | 2007 (1920-2093) | 2119 (1870-2368) | 0.185   |                     |  |  |  |
| 3.3-3.9   | 1689 (6.4) | 178 (12) | 1920 (1782-2795) | 2473 (1997-2949) | 0.005   | +29% (2.3 – 55)     |  |  |  |
| > 3.9   | 516 (2.0)  | 71 (4.6) | 1569 (1277-1861) | 2676 (2292-3060) | 0.002   | +71% (30 – 111)     |  |  |  |
| Median survival reported in days; derived from Kaplan-Meier analysis. P-value derived from log rank analysis. DKAS: Dual Kidney Allocation Score: eSKT: expanded criteria |            |          |                  |                  |         |                     |  |  |  |



Figure 4: Improved Median Survival when stratified by DKAS. Left: DKT and eSKT transplants (bars) and median graft survival (lines) for donors stratified by DKAS value. Right: Differences in percent median survival for DKT transplants over SKT for donors stratified by DKAS value. Error bars represent 95% confidence interval. DKT: Dual Kidney Transplant; eSKT: Single Kidney Transplant; DKAS: Dual Kidney Allocation Score.

# Acknowledgements and References

We would like to acknowledge UNOS for permitting the use and sharing of their data and the Department of Surgery at Thomas Jefferson University Hospital for funding the completion of this work. We would also like to thank all the donors and their families for the wonderful gifts of life they provide for the transplant community, without which none of this would be possible.

Ekser B, Furian L, Broggiato A, Silvestre C, Pierobon ES, Baldan N, et al. Technical aspects of unilateral dual kidney transplantation from expanded criteria donors: Experience of 100 patients. Am J Transplant. 2010;10(9):2000-7

| ECD: Expanded criteria donor; eSKT: expanded criteria single kidney transplant; DKT: |                |  |  |  |  |  |  |  |  |
|--|----------------|--|--|--|--|--|--|--|--|
| dual kidney transplant; HR   | : Hazard Ratio |  |  |  |  |  |  |  |  |



- E: adam.johnson@jefferson.edu
- E: cataldo.doria@jefferson.edu

single kidney transplant; DKT: dual kidney transplant; SE: Standard error